President Donald Trump's son-in-law Jared Kushner has presented a $50 billion investment plan for economic growth and peace in the Middle East that has been greeted with...World Politicsread more
Stocks should rally if the U.S. and China agree to new negotiations and a ceasefire in the trade war, but the economic impact of tariffs will continue.Market Insiderread more
The trade war between Beijing and Washington appears to have depressed Chinese property purchases in the United States. China's own actions may also be playing a role.Real Estateread more
Tesla CEO Elon Musk sent out another email to his employees, pushing them to aim for a record number of vehicle deliveries to end the second quarter of 2019.Technologyread more
More than 300 companies are talking to government officials in Washington about how detrimental the trade war is.Marketsread more
Democrats want Mueller's testimony on his probe into Russian interference in the 2016 election and Trump's efforts to influence it.Politicsread more
The Senate is expected to pass its own version of the border aid legislation, while the Trump administration has threatened to veto both bills.Politicsread more
Some 4 million people have fled the South American country since 2015 amid an economic meltdown.World Politicsread more
Japanese designer Undercover posted on its Instagram account a photo of protesters with the slogan "no extradition to China," the Financial Times reported.China Politicsread more
Powell stresses the central bank's independence in a speech that comes amid continuous pressure from the White House to cut interest rates.The Fedread more
Stocks in Asia were subdued on Wednesday after U.S. Federal Reserve Chairman Jerome Powell tempered expectations for a potential interest rate cut.Asia Marketsread more
An IPO for GE Healthcare this year is now in doubt, Culp said. Earlier reports incorrectly suggested the plans were off the table. Culp said GE is looking at the full spectrum of options for GE Healthcare, now that it will be without its biopharmaceutical business.
"We are focused on completing the carve out [of the biopharma business] — which is 15 percent of the $20 billion health-care segment — and focused on managing the remaining core business," the GE chairman and CEO told CNBC's Morgan Brennan.
"An IPO [for GE Healthcare] in 2019 looks unlikely at this point," Culp added.
GE filed confidential paperwork for an IPO of GE Healthcare in December.
The unit is a dominant player in hospital and lab equipment, generating roughly $19 billion in revenue and $3.4 billion in profit last year. It accounted for 15.8 percent of the conglomerate's total sales and 43.2 percent of its operating profit in 2017.
The company has previously said spinning out the health unit made sense because it would allow the company to double down on its core industrial and energy businesses.
"IPO of health care was Plan A, but we got lots of inbound calls about this business and this is clearly a superior path," Culp told CNBC's David Faber.
Additionally, according to Bloomberg, GE is still exploring options for its imaging business.
– CNBC's Berkeley Lovelace Jr. contributed to this report.